That is not quite true. Any potential drug that could raise the SOC that fails maintains the low bar of the current SOC. The recent MABs are failing in the marketplace and those are the only drugs that ever so slightly raised the SOC bar. That leaves the treatment vacuum in place. It is that treatment vacuum that 2-73 will fill on approval. The RAs understand that.
The need for AD treatment is great and as of now still an unfulfilled need.
As far as your reference to Rett is concerned, 2-73 for AD is well past the failure point of Rett which was not achieving statistical significance.
Market Data 
Markets 
AI
